NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-17-039 from the NIH Guide for Grants and Contracts. This FOA invites exploratory comparative biology research projects assessing how different animal species respond to challenges and damage to cellular physiology pathways that might influence the onset of Alzheimer's and other neurodegenerative diseases as well as resilience to them, such as adaptation to stress, macromolecular damage, proteostasis and stem cell function and regeneration.
Notice NOT-NS-17-005 from the NIH Guide for Grants and Contracts
Notice NOT-NS-17-006 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-17-056 from the NIH Guide for Grants and Contracts. This FOA invites applications on descriptive, basic and translational studies of APOE2 to delineate the functional effects of ApoE2 on healthy aging of the brain and other tissues. The primary focus is on the APOE2Aging-AD" relationship and the mechanistic effects of the protective variant on aging and potential interaction/cross talk between tissues in the aging process and AD. These studies are expected to generate new mechanistic insights that involve brain and/or other organs and assist in the identification of potential prognostic and diagnostic markers and therapeutic targets for AD and other age-related cognitive disorders. Eventually, the findings from these studies could lead to translational research opportunities not only to prevent or delay the onset of AD, but also to protect against multiple age-related conditions.
Funding Opportunity RFA-AG-17-051 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites innovative research focused on understanding the role of exosome biogenesis and secretion in modulating and propagation of early pathogenesis in sporadic and late-onset Alzheimers disease (AD). Specifically, this FOA encourages collaborative approaches designed to identify and characterize the regulation of molecular machines that are responsible for exosome biogenesis and the secretion of exosomal cargo molecules in AD.
Funding Opportunity RFA-HL-17-020 from the NIH Guide for Grants and Contracts. This FOA invites applications for clinical research to elucidate circadian-dependent mechanisms contributing to the pathophysiology of human obesity, diabetes-related metabolism, obesity-coupled risks for heart, lung, and blood disease, and the identification of novel therapies to improve circadian rhythm for primary or secondary prevention of obesity-associated disease risks. Multi-disciplinary, multiple-investigator teams proposing mechanistic clinical studies to elucidate the relationship of circadian rhythm to causal pathways of disease are encouraged. Studies of epidemiological risk and clinical trials to assess therapeutic efficacy, effectiveness, or implementation are outside the scope of this program.
Funding Opportunity PAR-17-031 from the NIH Guide for Grants and Contracts. This FOA encourages innovative experimental approaches to explore the molecular and cellular bases for age-related change in metabolism that impact the development of Alzheimer's disease (AD).
Notice NOT-HS-17-002 from the NIH Guide for Grants and Contracts
Notice NOT-DK-17-001 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-17-033 from the NIH Guide for Grants and Contracts. This FOA invites applications that apply a cross-disciplinary, team science approach to gain comprehensive, mechanistic understanding of the impact of sex differences on the trajectories of brain aging and phenotypes of AD risk and on the responsiveness to pharmacologic and non-pharmacologic interventions.
Funding Opportunity PAR-17-032 from the NIH Guide for Grants and Contracts. This funding opportunity invites applications that integrate the use of computational approaches to identify individual drugs currently used for other conditions with potential to be efficacious in AD or AD-related dementias (as single drugs or as drug combinations) with proof-of-concept efficacy studies in cell-based models, animal models and/or humans.
Notice NOT-AG-16-080 from the NIH Guide for Grants and Contracts
Notice NOT-AG-16-079 from the NIH Guide for Grants and Contracts
Notice NOT-AG-16-078 from the NIH Guide for Grants and Contracts
Notice NOT-AG-16-077 from the NIH Guide for Grants and Contracts
Notice NOT-LM-17-001 from the NIH Guide for Grants and Contracts
Notice NOT-OD-17-010 from the NIH Guide for Grants and Contracts
Notice NOT-TR-17-004 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-16-017 from the NIH Guide for Grants and Contracts. Population-based Research to Optimize the Screening Process (PROSPR) is the National Cancer Institute (NCI) program to promote research aimed at evaluating and improving the cancer screening process. As a part of the reissued PROSPR program, this Funding Opportunity Announcement (FOA) solicits applications for a PROSPR U24 Coordinating Center. A companion FOA (RFA-CA-16-016) will support PROSPR UM1 Research Centers. The overall goal for the PROSPR Research Centers is to enhance understanding of the implementation and effects of screening as practiced in multiple healthcare environments in the United States.
Funding Opportunity RFA-CA-16-016 from the NIH Guide for Grants and Contracts. Population-based Research to Optimize the Screening Process (PROSPR) is the National Cancer Institute (NCI) program to promote research aimed at evaluating and improving the cancer screening process. As a part of the reissued PROSPR program, this Funding Opportunity Announcement (FOA) solicits applications for PROSPR UM1 Research Centers. A companion FOA (RFA-CA-16-017) will support a PROSPR U24 Coordinating Center. The overall goal for PROSPR Research Centers is to enhance understanding of the implementation and effects of screening as practiced in multiple, heterogeneous healthcare environments in the United States. Therefore, the research programs proposed must cover long-term observations of diverse cohorts of patients who are eligible for screening. In addition to observational research to evaluate factors that affect the quality of the screening process for the selected cancer type, these programs should also develop and pilot-test interventions aimed at improving the screening process for that cancer.